Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta …

CH Suh, HS Park, KW Kim, J Pyo, H Hatabu, M Nishino - Lung cancer, 2018 - Elsevier
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
被引用次数：59 相关文章

Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta …

CH Suh, HS Park, KW Kim, J Pyo… - Lung cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

[引用][C] Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients

CH Suh, HS Park, KW Kim, J Pyo, H Hatabu, M Nishino - Lung Cancer, 2018 - cir.nii.ac.jp
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine
kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients | CiNii Research CiNii 国立 …

Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta …

CH Suh, HS Park, KW Kim, J Pyo, H Hatabu… - Lung Cancer …, 2018 - europepmc.org
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta …

CH Suh, HS Park, KW Kim, J Pyo, H Hatabu… - Lung …, 2018 - lungcancerjournal.info
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …